Literature DB >> 1979555

Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL.

G L Hamann1, T M Egan, B G Wells, J E Grimmig.   

Abstract

The authors report four cases of injection site reaction after intramuscular administration of haloperidol decanoate 100 mg/mL. In each case, the injection site became edematous, red, pruritic, and tender, and a palpable mass remained for up to 3 months. No systemic symptoms were reported. All four patients had previously received the 50 mg/mL haloperidol decanoate injection without incident. Two of these events followed the initial injection of haloperidol decanoate 100 mg/mL. Rechallenge with the 100 mg/mL product in one case and the 50 mg/mL product in two resulted in similar reactions. The incidence of this reaction at the authors' facility is estimated to be 7.7%. The authors speculate that the reaction is most likely to be related to the concentration of haloperidol decanoate in the injection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979555

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

1.  Complications at site of injection of depot neuroleptics.

Authors:  J Hay
Journal:  BMJ       Date:  1995-08-12

2.  Supra-therapeutic plasma concentrations of haloperidol induce moderate inhibition of lipopolysaccharide-induced interleukin-8 release in human monocytes.

Authors:  Herbert Bosshart
Journal:  Ann Transl Med       Date:  2016-10

3.  Deltoid injections of risperidone long-acting injectable in patients with schizophrenia.

Authors:  Jorge A Quiroz; Sarah Rusch; An Thyssen; Joseph M Palumbo; Stuart Kushner
Journal:  Innov Clin Neurosci       Date:  2011-06

Review 4.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

5.  Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.

Authors:  David P McDonnell; John Landry; Holland C Detke
Journal:  Int Clin Psychopharmacol       Date:  2014-11       Impact factor: 1.659

Review 6.  Prodrug strategies for enhancing the percutaneous absorption of drugs.

Authors:  David D N'Da
Journal:  Molecules       Date:  2014-12-12       Impact factor: 4.411

7.  Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Authors:  Simon Zhornitsky; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2012-02-15

8.  A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.

Authors:  Susan Atkins; Holland C Detke; David P McDonnell; Michael G Case; Shufang Wang
Journal:  BMC Psychiatry       Date:  2014-01-14       Impact factor: 3.630

9.  Long-acting atypical antipsychotics: characterization of the local tissue response.

Authors:  Sara Montminy Paquette; Had Dawit; Magali B Hickey; Elaine Merisko-Liversidge; Orn Almarsson; Daniel R Deaver
Journal:  Pharm Res       Date:  2014-02-21       Impact factor: 4.200

10.  Paliperidone Palmitate Associated with Necrotizing Deep Tissue Infection and Sepsis Requiring Surgical Intervention.

Authors:  Jonathan G Leung; Kirstin J Kooda; Erin N Frazee; Sarah Nelson; Katherine M Moore
Journal:  Case Rep Psychiatry       Date:  2015-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.